PTC124 Improves Readthrough and Increases Enzymatic Activity of the CPT1A R160X Nonsense Mutation

Overview

Journal J Inherit Metab Dis

Publisher Wiley

Date 2011 Jan 22

PMID 21253826

Citations 25

Authors

Lu Tan

Srinivas B Narayan

Jie Chen

Gail Ditewig Meyers

Michael J Bennett

Affiliations

Soon will be listed here.

Abstract

Deficiency of carnitine palmitoyltransferase 1A (CPT1A) results in impaired hepatic long-chain fatty acid oxidation and ketogenesis. We have previously described a patient with a severe CPT1A phenotype who is homozygous for the nonsense mutation 478 C > T (R160X). It has been known for some time that gentamicin can promote readthrough of nonsense codons. Recently, a new compound (PTC124) with less clinical toxicity than gentamicin has been indicated as a therapy for patients with nonsense mutations for multiple genetic diseases. The study is designed to investigate whether PTC124 can promote readthrough of the R160X CPT1A mutation and increase normal sized CPT1 protein expression and activity in the patient's skin fibroblasts. Our study demonstrated that after both PTC 124 and gentamicin treatment, there was an increase in CPT1 activity in patient fibroblasts to levels that are similar to that of the mild Inuit P479L variant. Our results provide additional evidence for proof of principle that PTC124 is a potential therapeutic agent for treating patients with any genetic condition that results from a nonsense mutation.

Citing Articles

Ataluren-Promising Therapeutic Premature Termination Codon Readthrough Frontrunner.

Michorowska S Pharmaceuticals (Basel). 2021; 14(8).

PMID: 34451881 PMC: 8398184. DOI: 10.3390/ph14080785.

Absence of p.R50X read-through in McArdle disease cellular models.

Tarraso G, Real-Martinez A, Pares M, Romero-Cortadellas L, Puigros L, Moya L Dis Model Mech. 2019; 13(1).

PMID: 31848135 PMC: 6994938. DOI: 10.1242/dmm.043281.

Serum starvation enhances nonsense mutation readthrough.

Wittenstein A, Caspi M, David Y, Shorer Y, Nadar-Ponniah P, Rosin-Arbesfeld R J Mol Med (Berl). 2019; 97(12):1695-1710.

PMID: 31786671 DOI: 10.1007/s00109-019-01847-0.

Clinical potential of ataluren in the treatment of Duchenne muscular dystrophy.

Namgoong J, Bertoni C Degener Neurol Neuromuscul Dis. 2018; 6:37-48.

PMID: 30050367 PMC: 6053089. DOI: 10.2147/DNND.S71808.

circRNA_0046366 inhibits hepatocellular steatosis by normalization of PPAR signaling.

Guo X, Sun F, Chen J, Wang Y, Pan Q, Fan J World J Gastroenterol. 2018; 24(3):323-337.

PMID: 29391755 PMC: 5776394. DOI: 10.3748/wjg.v24.i3.323.

References

ESSER V, Brown N, Cowan A, Foster D, McGarry J . Expression of a cDNA isolated from rat brown adipose tissue and heart identifies the product as the muscle isoform of carnitine palmitoyltransferase I (M-CPT I). M-CPT I is the predominant CPT I isoform expressed in both white (epididymal) and brown.... J Biol Chem. 1996; 271(12):6972-7. DOI: 10.1074/jbc.271.12.6972. View

Greenberg C, Dilling L, Thompson G, Seargeant L, Haworth J, Phillips S . The paradox of the carnitine palmitoyltransferase type Ia P479L variant in Canadian Aboriginal populations. Mol Genet Metab. 2009; 96(4):201-7. DOI: 10.1016/j.ymgme.2008.12.018. View

Buck N, Wood L, Hu R, Peters H . Stop codon read-through of a methylmalonic aciduria mutation. Mol Genet Metab. 2009; 97(4):244-9. DOI: 10.1016/j.ymgme.2009.04.004. View

Kerem E, Hirawat S, Armoni S, Yaakov Y, Shoseyov D, Cohen M . Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial. Lancet. 2008; 372(9640):719-27. DOI: 10.1016/S0140-6736(08)61168-X. View

Du M, Liu X, Welch E, Hirawat S, Peltz S, Bedwell D . PTC124 is an orally bioavailable compound that promotes suppression of the human CFTR-G542X nonsense allele in a CF mouse model. Proc Natl Acad Sci U S A. 2008; 105(6):2064-9. PMC: 2538881. DOI: 10.1073/pnas.0711795105. View

Forge A, Schacht J . Aminoglycoside antibiotics. Audiol Neurootol. 2000; 5(1):3-22. DOI: 10.1159/000013861. View

Rajakumar C, Ban M, Cao H, Young T, Bjerregaard P, Hegele R . Carnitine palmitoyltransferase IA polymorphism P479L is common in Greenland Inuit and is associated with elevated plasma apolipoprotein A-I. J Lipid Res. 2009; 50(6):1223-8. PMC: 2681405. DOI: 10.1194/jlr.P900001-JLR200. View

Welch E, Barton E, Zhuo J, Tomizawa Y, Friesen W, Trifillis P . PTC124 targets genetic disorders caused by nonsense mutations. Nature. 2007; 447(7140):87-91. DOI: 10.1038/nature05756. View

Bennett M, Boriack R, Narayan S, Rutledge S, Raff M . Novel mutations in CPT 1A define molecular heterogeneity of hepatic carnitine palmitoyltransferase I deficiency. Mol Genet Metab. 2004; 82(1):59-63. DOI: 10.1016/j.ymgme.2004.02.004. View

10.

Nagai J, Takano M . Molecular aspects of renal handling of aminoglycosides and strategies for preventing the nephrotoxicity. Drug Metab Pharmacokinet. 2004; 19(3):159-70. DOI: 10.2133/dmpk.19.159. View

11.

Schmitz A, Famulok M . Chemical biology: ignore the nonsense. Nature. 2007; 447(7140):42-3. DOI: 10.1038/nature05715. View

12.

Finkel R . Read-through strategies for suppression of nonsense mutations in Duchenne/ Becker muscular dystrophy: aminoglycosides and ataluren (PTC124). J Child Neurol. 2010; 25(9):1158-64. PMC: 3674569. DOI: 10.1177/0883073810371129. View

13.

Brown N, Mullur R, Subramanian I, ESSER V, Bennett M, Saudubray J . Molecular characterization of L-CPT I deficiency in six patients: insights into function of the native enzyme. J Lipid Res. 2001; 42(7):1134-42. View